Literature DB >> 17171643

Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize.

Dai Fukumura1, Rakesh K Jain.   

Abstract

A solid tumor is an organ-like entity comprised of neoplastic cells and non-transformed host stromal cells embedded in an extracellular matrix. The expression of various genes is influenced by interactions among these cells, surrounding matrix, and their local physical and biochemical microenvironment. The products encoded by these genes, in turn, control the pathophysiological characteristics of the tumor, and give rise to the abnormal organization, structure, and function of tumor blood vessels. These abnormalities contribute to heterogeneous blood flow, vascular permeability, and microenvironment. Proliferating tumor cells produce solid stress which compresses blood and lymphatic vessels. As a result of vessel leakiness and lack of functional lymphatics, interstitial fluid pressure is significantly elevated in solid tumors. Each of these abnormalities forms a physiological barrier to the delivery of therapeutic agents to tumors. Furthermore, the metabolic microenvironment in tumors such as hypoxia and acidosis hinder the efficacy of anti-tumor treatments such as radiation therapy and chemotherapy. A judicious application of anti-angiogenic therapy has the potential to overcome these problems by normalizing the tumor vessels and making them more efficient for delivery of oxygen and drugs. Combined anti-angiogenic and conventional therapies have shown promise in the clinic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17171643     DOI: 10.1002/jcb.21187

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  177 in total

1.  Interstitial fluid pressure correlates with intravoxel incoherent motion imaging metrics in a mouse mammary carcinoma model.

Authors:  Sungheon Kim; Lindsey Decarlo; Gene Y Cho; Jens H Jensen; Daniel K Sodickson; Linda Moy; Silvia Formenti; Robert J Schneider; Judith D Goldberg; Eric E Sigmund
Journal:  NMR Biomed       Date:  2011-11-09       Impact factor: 4.044

2.  Evaluation of tumor microenvironment in an animal model using a nanoparticle contrast agent in computed tomography imaging.

Authors:  Ketan B Ghaghada; Cristian T Badea; Lohitash Karumbaiah; Nicole Fettig; Ravi V Bellamkonda; G A Johnson; Ananth Annapragada
Journal:  Acad Radiol       Date:  2011-01       Impact factor: 3.173

3.  A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).

Authors:  Karen E Bullock; William P Petros; Islam Younis; Hope E Uronis; Michael A Morse; Gerard C Blobe; S Yousuf Zafar; Jon P Gockerman; Joanne J Lager; Roxanne Truax; Kellen L Meadows; Leigh A Howard; Margot M O'Neill; Gloria Broadwater; Herbert I Hurwitz; Johanna C Bendell
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-16       Impact factor: 3.333

Review 4.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

Review 5.  Magnetic resonance-guided focused ultrasound: a new technology for clinical neurosciences.

Authors:  Ferenc A Jolesz; Nathan J McDannold
Journal:  Neurol Clin       Date:  2013-11-08       Impact factor: 3.806

Review 6.  Therapeutic potential of midkine in cardiovascular disease.

Authors:  Kenji Kadomatsu; Péter Bencsik; Anikó Görbe; Csaba Csonka; Kazuma Sakamoto; Satoshi Kishida; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 7.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

Review 8.  Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.

Authors:  Muna Aryal; Costas D Arvanitis; Phillip M Alexander; Nathan McDannold
Journal:  Adv Drug Deliv Rev       Date:  2014-01-22       Impact factor: 15.470

9.  Neutralizing endogenous VEGF following traumatic spinal cord injury modulates microvascular plasticity but not tissue sparing or functional recovery.

Authors:  Richard L Benton; Melissa A Maddie; Mark J Gruenthal; Theo Hagg; Scott R Whittemore
Journal:  Curr Neurovasc Res       Date:  2009-05       Impact factor: 1.990

Review 10.  Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Authors:  NaTosha N Gatson; E Antonio Chiocca; Balveen Kaur
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.